Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice.

Autor: Song Y; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Bugada L; Department of Chemical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI 48109, USA., Li R; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Hu H; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Zhang L; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Li C; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Yuan H; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Rajanayake KK; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Truchan NA; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Wen F; Department of Chemical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI 48109, USA., Gao W; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Sun D; Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2022 May 04; Vol. 14 (643), pp. eabl3649. Date of Electronic Publication: 2022 May 04.

Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy.

Autor: Yu Huang¹, Hui Fan² fanhui@gdpu.edu.cn, Huihui Ti^1,3 tihuihui@126.com

Publikováno v: Asian Journal of Pharmaceutical Sciences. Apr2024, Vol. 19 Issue 2, p1-37. 37p.

Engineered exosomes-based theranostic strategy for tumor metastasis and recurrence.

Autor: Min Deng¹, Shuang Wu², Peizheng Huang¹, Yun Liu³ yunliu@cqmu.edu.cn, Chong Li^2,4 chongli@swu.edu.cn, Ji Zheng¹ jizheng023@aliyun.com

Publikováno v: Asian Journal of Pharmaceutical Sciences. Nov2023, Vol. 18 Issue 6, p1-27. 27p.

Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer.

Autor: Zhou, Yuxin¹ (AUTHOR) charlotte_zyx@outlook.com, Liao, Minru¹ (AUTHOR) 15680965456@163.com, Li, Zixiang² (AUTHOR) li69010@163.com, Ye, Jing¹ (AUTHOR) scuyj0222@163.com, Wu, Lifeng¹ (AUTHOR) 18482273923@163.com, Mou, Yi¹ (AUTHOR) skayhy@163.com, Fu, Leilei² (AUTHOR) leilei_fu@swjtu.edu.cn, Zhen, Yongqi¹ (AUTHOR) leilei_fu@swjtu.edu.cn

Publikováno v: International Journal of Molecular Sciences. Oct2023, Vol. 24 Issue 20, p15121. 18p.

Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges.

Autor: Liu, Junxia¹ (AUTHOR) d202282220@hust.edu.cn, Chao, Tengfei¹ (AUTHOR) tengfeichao@tjh.tjmu.edu.cn, Liu, Yingying² (AUTHOR) yangyang21@sjtu.edu.cn, Gong, Chen¹ (AUTHOR) chengong@tjh.tjmu.edu.cn, Zhang, Yinan³ (AUTHOR) yinan_zhang@tongji.edu.cn, Xiong, Huihua¹ (AUTHOR) yinan_zhang@tongji.edu.cn

Publikováno v: Pharmaceutics. Jun2023, Vol. 15 Issue 6, p1706. 18p.